# Radionetics Oncology

Source: https://onco.cc/companies/radionetics-oncology/  
OnCo record `radionetics-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Radionetics Oncology makes small-molecule drugs that carry a radioactive isotope to receptors on the surface of cancer cells that have rarely been targeted before. Eli Lilly paid 140 million dollars in 2024 for the right to buy the company for 1 billion dollars.

## Summary

Radionetics Oncology, a San Diego company that emerged from Crinetics Pharmaceuticals in October 2021, discovers and develops small-molecule radiopharmaceuticals against G protein-coupled receptor (GPCR) targets not previously pursued by radiopharmaceuticals, identified through AI-driven multi-omics. Its first phase 1 radiopharmaceutical programme, against a novel target for adrenocortical carcinoma, was initiated in October 2023. In January 2024 the company raised a USD 52.5 million Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, appointing Paul Grayson as CEO. In July 2024 it entered a strategic agreement with Eli Lilly under which Radionetics received a USD 140 million upfront payment and Lilly obtained the exclusive right to acquire the company for USD 1 billion after an exercise period, during which Radionetics continues to build its GPCR-targeted pipeline.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: San Diego, CA
- Type: radiopharma
- Website: https://radionetics.com/

## Notes

- The USD 140 million Lilly upfront payment is a strategic agreement, not an equity round, so it is described in the summary rather than in funding.

## Sources

- Official website: https://radionetics.com/
- Series A press release: https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a
- Lilly strategic agreement release: https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- companies: [5AM Ventures](https://onco.cc/companies/5am-ventures/), [DCVC](https://onco.cc/companies/dcvc/), [Frazier Life Sciences](https://onco.cc/companies/frazier-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/radionetics-oncology.json